Sign in
Taking people in South KoreaNo phase

Comparing two treatments for narrowed heart arteries

Compares two procedures for narrowed heart arteries in adults with coronary artery disease.

Key facts

Who runs it
Chonnam National University Hospital
Where
Busan, Daegu, Gwangju, Jeonju, Seoul, and Ulsan, South KoreaSee the 8 sites
Trial code
Registry title
Late-lumen Changes After Drug-Coated Balloon Angioplasty Versus Drug-Eluting Stents in De Novo Coronary Lesions
Status
Recruiting
People taking part
256 people, planned
Started
18 Aug 2025
Expected to end
31 Dec 2028
Type of study
Interventional, 2 groupsOne group gets an existing treatment, for comparison.
Treatments tested
  • Drug-eluting stent implantation
  • Drug-coated balloon angioplasty
Record updated
22 October 2026

Who can take part

AI summary

From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.

The trial is looking for adults with a new narrowing in a heart artery that needs treatment to open it. It compares a drug-coated balloon with a drug-eluting stent.

Age
19 years or older
Sex
All sexes can join
Disease stage
At least one new (de novo) narrowing in a heart artery, more than 50% narrowed or with a fractional flow reserve of 0.80 or lower, in an artery 3.0 mm or wider, needing treatment to restore blood flow

Main reasons for not taking part

  • Narrowing of the left main heart artery
  • Narrowing inside an old stent, or in a bypass graft
  • Cardiogenic shock or cardiac arrest
  • Severe weakness of the left heart pumping (ejection fraction under 30%)
  • Pregnant or breastfeeding women

The registry criteria, word for word

Show all 12 criteriaShow less

Who can take part

  • Subject must be at least 19 years of age
  • Subject who is able to understand risks, benefits and treatment alternatives and sign informed consent voluntarily
  • Patients with at least one lesion with greater than 50% diameter stenosis or fractional flow reserve ≤0.80 requiring revascularization in de-novo coronary artery of reference vessel size ≥3.0 mm

Who cannot take part

  • Patients with known intolerance to aspirin, P2Y12 inhibitors, or components of drug-eluting stents
  • Patients with angiographic findings of 1) Left main coronary artery disease 2) In-stent restenosis is the cause of target lesion 3) Target lesion in bypass graft 4) True bifurcation lesion that requires upfront 2-stenting
  • Patients who have non-cardiac co-morbid conditions with life expectancy <1 year
  • Patients with cardiogenic shock or cardiac arrest
  • Patients with severe valvular heart disease requiring open heart surgery
  • Patients with severe left ventricular systolic dysfunction (ejection fraction <30%)
  • Patients unable to provide consent
  • Patients who may result in protocol non-compliance (site investigator's medical judgment)
  • Pregnant or lactating women

Where in South Korea

  • Kosin University Gospel HospitalBusan, South KoreaContact: Jung Ho Heo, MD, PhDNot yet recruiting
  • Keimyung University Dongsan HospitalDaegu, South KoreaContact: Hyuck-Jun Yoon, MD, PhDNot yet recruiting
  • Chonnam National UniversityGwangju, South KoreaContact: Young Joon Hong, MD, PhDTaking people
  • jeonbuk National University HospitalJeonju, South KoreaContact: Yi Sik Kim, MD, PhDNot yet recruiting
  • Ewha Womans University Mokdong HospitalSeoul, South KoreaContact: Sodam Jung, MD, PhDNot yet recruiting
  • Korea University Guro HospitalSeoul, South KoreaContact: Dong Oh Kang, MD, PhDNot yet recruiting
  • Samsung Medical CenterSeoul, South KoreaContact: Joo Myung Lee, MD, PhDNot yet recruiting
  • Ulsan University HospitalUlsan, South KoreaContact: Eun Seok Shin, MD, PhDNot yet recruiting

About the trial

What the trial wants to find out

This study aims to compare late-lumen loss (LLL) between DCB and DES to treat de novo coronary artery stenosis by intravascular ultrasound (IVUS).

The 2 groups in the trial

  • Drug-eluting stentExisting treatment, for comparison

    In DES group, latest second-generation DES will be used in accordance with standard practice guideline.

    Treatment: Drug-eluting stent implantation

  • Drug-coated balloonTreatment being tested

    In DCB group, commercially available DCB (Agent, Boston Scientific, USA) will be used. DCB angioplasty will be recommended as follows to fully optimized procedural results. First, DCB size should be 1:1 ratio with reference vessel size. Second, delivery time of DCB should be within 30 seconds. Third, total inflation time of DCB will be recommended from 30 to 60 seconds.

    Treatment: Drug-coated balloon angioplasty

Questions to ask the study team

  1. How often do I need to come in, and for how long each time?
  2. Are travel costs paid?
  3. Can I keep my own doctor?
  4. What happens if I want to stop?

Contact the study team: see the registry record → Contacts and Locations

Print a page for my doctor

Data and sources

Registry record
Listed on ClinicalTrials.gov.How to verify a trial in the registry
Official title
Late-lumen Changes After Drug-Coated Balloon Angioplasty Versus Drug-Eluting Stents in De Novo Coronary Lesions
Plain-language title
Comparing two treatments for narrowed heart arteriesGenerated from the registry record. The registry title is the official one.
AI summary
From the trial's eligibility criteria. Read by machine on 12 November 2026.
Record updated
22 October 2026